Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 38-43

  Hayette, Sandrine ^a,f   Chabane, Kaddour ^a   Michallet, Mauricette ^b,f   Michallat, Estelle ^a   Cony Makhoul, Pascale ^c,f   Salesse, Stéphanie ^d   Maguer Satta, Véronique ^e   Magaud, Jean Pierre ^a   Nicolini, Franck E ^b,f  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c Metz Tessy   (France)

^d UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^e INSERM   (France)

^f French Intergroup of CML (Fi LMC Group)   (France)

Author keywords

BCR ABL resistance; CML; SRC Kinases; Tyrosine Kinase Inhibitors

Indexed keywords

BCR ABL PROTEIN; BRUTON TYROSINE KINASE; DASATINIB; HEMATOPOIETIC CELL KINASE; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PROTEIN KINASE LYN;

ARTICLE; BLAST CELL CRISIS; CANCER GROWTH; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LONGITUDINAL STUDIES; PIPERAZINES; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 78650127969     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.030     Document Type: Article

References (31)

1. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
2. Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996, 56:3589-3596.
3. Roginskaya V., Zuo S., Caudell E., Nambudiri G., Kraker A.J., Corey S.J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999, 13:855-861.
4. Ptasznik A., Nakata Y., Kalota A., Emerson S.G., Gewirtz A.M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004, 10:1187-1189.
5. Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008, 111:3821-3829.
6. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
7. Mahon F.X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008, 68:9809-9816.
8. Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453-461.
9. Lionberger J.M., Wilson M.B., Smithgall T.E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000, 275:18581-18585.
10. Scapini P., Pereira S., Zhang H., Lowell C.A. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 2009, 228:23-40.
11. Miyoshi N., Tanaka H., Ito T., Katayama Y., Niimi H., Hyodo H., et al. Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase. Int J Hematol 2005, 82:333-337.
12. Hofmann W.K., de Vos S., Elashoff D., Gschaidmeier H., Hoelzer D., Koeffler H.P., et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002, 359:481-486.
13. Dai Y., Rahmani M., Corey S.J., Dent P., Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004, 279:34227-34239.
14. Miething C., Mugler C., Grundler R., Hoepfl J., Bai R.Y., Peschel C., et al. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo. Leukemia 2003, 17:1695-1699.
15. Meyn M.A., Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J., et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006, 281:30907-30916.
16. Luciano F., Ricci J.E., Auberger P. Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation. Oncogene 2001, 20:4935-4941.
17. Gamas P., Marchetti S., Puissant A., Grosso S., Jacquel A., Colosetti P., et al. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Leukemia 2009, 23:1500-1506.
18. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109:2303-2309.
19. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
20. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
21. Rawlings D.J., Scharenberg A.M., Park H., Wahl M.I., Lin S., Kato R.M., et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996, 271:822-825.
22. Villuendas R., Steegmann J.L., Pollan M., Tracey L., Granda A., Fernandez-Ruiz E., et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006, 20:1047-1054.
23. Hantschel O., Rix U., Schmidt U., Burckstummer T., Kneidinger M., Schutze G., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007, 104:13283-13288.
24. Kubo T., Kuroda Y., Kokubu A., Hosoda F., Arai Y., Hiraoka N., et al. Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. Pancreas 2009, 38:e200-206.
25. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
26. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
27. Chu S., Xu H., Shah N.P., Snyder D.S., Forman S.J., Sawyers C.L., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105:2093-2098.
28. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003, 17:2474-2486.
29. Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B., Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008, 111:2269-2279.
30. Chen Y., Hu Y., Michaels S., Segal D., Brown D., Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009, 23:1446-1454.
31. Chen R., Gandhi V., Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006, 66:10959-10966.